文献类型：期刊文献

中文题名：宣肺化浊加减方治疗新型冠状病毒肺炎40例临床疗效观察

英文题名：Clinical Efficacy of Xuanfei Huazhuo Prescription on 40 Cases of COVID-19

作者：史桐凡[1];周谷城[1];张利英[1];牛帆[2];柯宜诚[1];周婷[1];王庆胜[2];靳晓杰[1];刘东玲[1];魏本君[1];张卫强[2];张志明[2];刘永琦[1]

第一作者：史桐凡

机构：[1]甘肃中医药大学,甘肃省高校重大疾病分子医学与中医药防治研究重点实验室,敦煌医学与转化省部共建教育部重点实验室,兰州730000;[2]甘肃中医药大学附属医院,兰州730000

第一机构：甘肃中医药大学科研实验中心（甘肃省中医药标准化技术委员会秘书处）

年份：2020

卷号：26

期号：16

起止页码：26

中文期刊名：中国实验方剂学杂志

外文期刊名：Chinese Journal of Experimental Traditional Medical Formulae

收录：CSTPCD;;北大核心:【北大核心2017】；CSCD:【CSCD2019_2020】；

基金：甘肃省新型冠状病毒肺炎(COVID-19)科技重大专项(2020年);甘肃省高校重大疾病分子医学与中医药防治研究重点实验室COVID-19防治科研专项开放基金项目(FZYX20-2,FZYX20-6,FZYX20-8);兰州市城关区新型冠状病毒肺炎科技专项(2020JSCX0025)。

语种：中文

中文关键词：宣肺化浊方;新型冠状病毒肺炎(COVID-19);症状;中医治疗;疗效

外文关键词：Xuanfei Huazhuo prescription;coronavirus disease-2019(COVID-19);symptom;treatment with traditional Chinese medicine;efficacy

摘要：目的:评价使用宣肺化浊加减方治疗新型冠状病毒肺炎(COVID-19)的临床疗效。方法:选取40例确诊为COVID-19且用宣肺化浊加减方治疗的患者,观察患者在用宣肺化浊方前后体温,临床症状,计算机体层摄影(CT),血常规,生化指标等方面的变化情况。结果:40例患者中男15例,女25例,男女比例为1∶1. 7,年龄20~94岁,平均(43. 9±16. 3)岁,病程8~23 d,平均(14±4. 4)d。与用药前比较,患者咳嗽、发热、咳痰、腹泻、食欲不振和乏力等临床症状皆有好转(P<0. 05);用药前患者中医证型主要为寒湿郁肺(57. 5%)和寒湿犯肺(42. 5%),舌苔主要为白腻苔(52. 9%);经宣肺化浊方辅助治疗后患者退热时间为(2. 48±2. 56)d;患者患者白细胞总数(WBC),淋巴细胞百分比(LYM%),中性粒细胞百分比(NEUT%),淋巴细胞绝对值(LYM#),C反应蛋白(CRP),红细胞沉降率(ESR),总胆红素(TBIL),天门冬氨酸氨基转移酶与丙氨酸氨基转移酶比值(AST/ALT)和乳酸脱氢酶(LDH)等指标较用药前基本恢复至正常范围(P<0. 05);经宣肺化浊加减方辅助治疗后,咽试子病毒核酸检测3次阴性,肺部CT示感染病灶已吸收,40例患者均符合出院标准已全部治愈出院,治愈率为100%,至今未有发生核酸检测转阳者复发病例;患者用药后症状与临床指标积分为(1. 62±1. 90),较用药前积分(7. 65±4. 08)明显降低(P<0. 05)。结论:宣肺化浊加减方辅助治疗新冠肺炎可以降低体温、促进肺部炎症吸收、改善发烧、咳嗽等临床症状。
Objective: To evaluate the clinical efficacy of Xuanfei Huazhuo prescription in the treatment of coronavirus disease-2019(COVID-19). Method: A total of 40 patients with COVID-19 were selected and treated with Xuanfei Huazhuo prescription. The changes of body temperature,clinical symptoms,computed tomography(CT),blood routine and biochemical indexes were observed before and after treatment.Result: The 40 patients included 15 males and 25 females,with a male to female ratio of 1∶1. 7. They were aged between 20-94 years old,with the average age of(43. 9±16. 3)years old. The course of disease was 8-23 days, with the average of(14±4. 4) days. Compared with before administration, the patients’ clinical symptoms,such as cough,fever,sputum,diarrhea,loss of appetite and fatigue,were all improved(P<0. 05).Before treatment the traditional Chinese medicine(TCM)syndromes of patients were mainly cold dampness lung(57. 5%)and cold dampness Lung(42. 5%),and the tongue coating was mainly white greasy coating(52. 9%). After adjuvant treatment with Xuanfei Huazhuo prescription,the fever removal time was(2. 48±2. 56)days;white blood cell(WBC),lymphocyte percentage(LYM%),neutrophil percentage(NEUT%),absolute value of lymphocytes(LYM #)indexes of C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),total bilirubin(TBIL),ratio of glutamic oxaloacetic transaminase to glutamic pyruvic transaminase(AST/ALT)and lactate dehydrogenase(LDH)were basically restored to the normal range(P<0. 05)compared with before administration. After adjuvant treatment with Xuanfei Huazhuo prescription,the results of three pharyngeal test virus nucleic acid tests were negative,and the lung CT showed that infected lesions were absorbed and all met the discharge criteria. All 40 patients met the discharge criteria and were all cured and discharged,with a cure rate of 100%. There has been no case of recurrence with a positive result of nucleic acid detection so far. The score of symptom and clinical index of patients after administration was(1. 62±1. 90),which was significantly lower than that before administration(7. 65±4. 08,P<0. 05). Conclusion: In the adjuvant treatment of COVID-19,Xuanfei Huazhuo prescription can reduce body temperature,promote the absorption of pulmonary inflammation,and improve clinical symptoms,such as fever and cough.